UVEITIS INA RHEUMATOLOGISTS PRACTICE: A ROLE OF TUMOR NECROSIS FACTOR-а INHIBITORS
Uveitis frequently develops in patients with ankylosing spondylitis (AS) and other autoimmune diseases. It is occasionally characterized by a severe recurrent course and untreatable with systemic glucocorticoids (GC) and standard immunosuppressive agents. The results of (mainly small) clinical trial...
Main Author: | Sergey Valentinovich Moiseyev |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IMA-PRESS LLC
2009-12-01
|
Series: | Современная ревматология |
Subjects: | |
Online Access: | https://mrj.ima-press.net/mrj/article/view/262 |
Similar Items
-
The effect of infliximab, cyclosporine A and recombinant IL-10 on vitreous cytokine levels in experimental autoimmune uveitis
by: Demir Tamer, et al.
Published: (2006-01-01) -
Perspectives for uveitis treatment in rheumatic diseases
by: Alla Aleksandrovna Godzenko, et al.
Published: (2011-06-01) -
Current standardized therapeutic approach for uveitis in Japan
by: Kazuichi Maruyama
Published: (2019-07-01) -
The Efficacy and Safety of Infliximab in Refractory Noninfectious Uveitis: A Meta-Analysis of Observational Studies
by: Anji Xiong, et al.
Published: (2021-09-01) -
Anti-infliximab antibodies and clinical response in noninfectious uveitis and scleritis patients treated with infliximab: A retrospective review
by: Cox, J.T, et al.
Published: (2022)